Webinar

The New Subcutaneous (SC) Landscape: Adapting Drug Delivery for Biologics Administration at Home

  • How the shift from IV infusion to large-volume subcutaneous self-administration is transforming biologic drug delivery — and what it demands from primary packaging components
  • How Datwyler's NeoFlex™ V9621 plunger meets the CCI, break-loose force, glide force, and extractables and leachables requirements of sensitive biologics in 20mL on-body wearable injector systems
  • The first documented evidence of accurate 20mL subcutaneous self-administration — CCI, dose accuracy, delivery time, and hold-up volume data from a collaboration with Stevanato Group, LTS Device Technologies, and Grand River Aseptic Manufacturing

Status Published
Format Webinar
Language English
Access Registration Required
Watch the Webinar
Resource Overview

About this Webinar

The subcutaneous drug delivery landscape is undergoing a structural transformation. Growing biologic use for chronic disease management, patient demand for home-based self-administration, and healthcare systems' recognition that decentralized injectable therapy reduces cost of care and improves adherence are collectively driving large-volume subcutaneous injection — volumes of 5–20mL previously exclusive to IV hospital administration — into on-body wearable injector platforms.

This on-demand webinar, presented by Datwyler's Product Manager for Prefilled Syringes and Cartridges, provides a comprehensive market analysis and technical deep dive into this emerging segment — including the first documented evidence of accurate 20mL subcutaneous self-administration using a fully integrated on-body injection system.

KEY TOPICS COVERED

Market drivers and the IV-to-SC transition

The webinar opens with an analysis of the primary drivers accelerating the shift from IV to subcutaneous administration: patient comfort, improved adherence, and measurable cost savings for healthcare systems managing chronic biologic therapies. Large-volume SC delivery addresses a critical gap between clinic-bound IV infusion and the convenience of home self-injection.

Primary packaging requirements for large-volume SC systems

Plunger seals for sensitive biologics in large-volume SC systems must meet stringent requirements across extractables and leachables, container closure integrity, particulate control, silicone management, and device compatibility. For wearable injectors, consistent break-loose and glide force performance across storage conditions is not a secondary consideration — it is a device actuation requirement.

NeoFlex™ plunger portfolio for large-volume cartridge formats

Datwyler's expanded NeoFlex™ plunger portfolio covers 5mL, 10mL, and 20mL pharmaceutical cartridge formats, aligned to ISO 13926-1 standards. The V9621 extends proven NeoFlex™ performance to the 20mL format, building on the commercial 10mL platform.

Collaborative case study: 20mL on-body injection system

The webinar presents a collaborative case study combining Datwyler's V9621 NeoFlex™ plunger, Stevanato Group's EZ-fill® 20mL pharmaceutical cartridge, LTS Device Technologies' Sorrel™ wearable platform, and Grand River Aseptic Manufacturing for fill-finish. One-month stability data demonstrates break-loose forces compatible with the Sorrel™ device vacuum limits, stable glide forces at both 5–8°C and 20°C storage, dose accuracy within ±5% across all configurations, and hold-up volume minimization through cone plunger geometry. This extends Datwyler's proven plunger performance across format types, building on the company's broader portfolio for pharmaceutical cartridges.

WHO THIS WEBINAR IS FOR

This session is designed for formulation scientists, packaging engineers, drug delivery device teams, and regulatory affairs professionals evaluating primary packaging components for large-volume subcutaneous biologics in wearable injector and on-body delivery platforms.
Watch the Webinar

Watch the Webinar On-Demand

Start the on-demand session instantly after quick registration.

Watch the Webinar
Quick access in under 30 seconds.
Expert Spotlight

Meet the Expert

Paolo Ferrigno

Paolo Ferrigno

Product Manager, Prefilled Syringes and Cartridges · Datwyler
In the industry of primary parenteral packaging since 2017, Paolo Ferrigno is the product manager for prefilled syringes and cartridge components at Datwyler Healthcare. At Datwyler, Ferrigno has covered different commercial and technical roles before landing back in product management in 2022. Educated in electronics and later in marketing, Ferrigno has had a wide range of experiences spanning R&D for audio/electronics in the automotive and consumer markets and product management for B2B distribution of industrial and electronics components. 
Email LinkedIn
Continue Exploring

More Biologics Resources

Explore additional resources connected to this topic.

Lyophilization is growing in pharma, but technical challenges persist
Technical Article

Lyophilization is growing in pharma, but technical challenges persist

In this technical article, Datwyler's Camille Ermine explores how lyophilization is reshaping pharmaceutical packaging decisions for biologics, mRNA therapeutics, ADCs, and orphan drugs — covering stopper geometry, moisture control, container closure integrity, and extractables and leachables risk, and how the right component choices help manufacturers navigate the fill-finish challenges that come with freeze drying.
Explore Resource →
Vial Packaging for the Biologics Market: Trends, Requirements, and Solutions
White Paper 2026 Report

Vial Packaging for the Biologics Market: Trends, Requirements, and Solutions

Biologics are projected to reach $881 billion in sales by 2030, yet their structural complexity makes packaging one of the most critical variables in drug safety and efficacy. This report examines the unique challenges of vial packaging for biologics — from extractables and leachables to lyophilization and regulatory compliance — and how advanced stopper technologies are engineered to meet them.
Explore Resource →
Designing vial systems to meet the demands of complex biologics
Technical Article

Designing vial systems to meet the demands of complex biologics

As biologics increasingly dominate the drug development pipeline, vial systems must do far more than contain a drug. This article from Pharmaceutical Technology explores the critical role of vial packaging in protecting complex large molecules — from managing extractables and leachables to enabling lyophilization — and how elastomer stopper design directly impacts drug stability, manufacturing efficiency, and patient safety.
Explore Resource →
Helpful Information

Frequently Asked Questions

What does this webinar cover?
This webinar examines the structural shift toward large-volume subcutaneous self-administration for biologics — covering market drivers, primary packaging requirements for wearable injector systems, Datwyler's NeoFlex™ V9621 plunger for 20mL pharmaceutical cartridge formats, and a collaborative case study presenting the first documented evidence of accurate 20mL on-body subcutaneous delivery.
When did this webinar take place?
The live session took place on January 29, 2026. The full recording is available on-demand.
Is this webinar available on-demand?
Yes. The full session is available to watch on-demand after a short registration, typically completed in under 30 seconds.
Who presented this webinar?
Paolo Ferrigno, Product Manager for Prefilled Syringes and Cartridges at Datwyler Healthcare, presented the session. The case study data was produced in collaboration with Stevanato Group, LTS Device Technologies, and Grand River Aseptic Manufacturing.
What is the NeoFlex™ V9621 plunger?
The V9621 is Datwyler's NeoFlex™ plunger for 20mL pharmaceutical cartridges, built on the FM457 BIMS substrate with a covalently bonded fluoropolymer coating that eliminates the need for siliconization and minimizes extractables and leachables risk. It extends proven NeoFlex™ geometry — undercut design, asymmetric orientation, cone dead-volume reduction — from the commercial 10mL platform to the emerging 20mL large-volume SC segment.
What is a wearable injector and why does packaging matter?
A wearable injector, such as the LTS Sorrel™ platform, is an on-body device that delivers large subcutaneous volumes — typically 5–20mL — over an extended period while the patient goes about their daily life. Packaging components, particularly plungers, must maintain consistent break-loose and glide force performance across storage conditions to ensure the device actuates correctly and delivers the full dose accurately. Container closure integrity, low particulate levels, and extractables and leachables compliance are equally critical for the sensitive biologic formulations typically delivered via these platforms.
TECHNICAL RESOURCES

Stay informed on Datwyler Healthcare technical resources

Subscribe to receive updates on webinars, white papers, technical articles, brochures, and expert insights from our team.